Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine and Haplo-identical NK Cells in AML
NCT02316964Phase 1Completed
- Start
- Apr 2015
- Primary completion
- Dec 2017
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial in acute myeloid leukemia (AML). Primary endpoints: Incidence of toxicities graded by using the Common Terminology Criteria for Adverse Events (CTCAE) version 4 at 28 days and Dose Limiting Toxicities at 4 hours. Started Apr 2015; status: completed.
02
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02316964.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02316964.